Abstract
Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Current Signal Transduction Therapy
Title:Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Volume: 8 Issue: 3
Author(s): Iwona Anna Ciechomska, Marta Kocyk and Bozena Kaminska
Affiliation:
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Abstract: Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Export Options
About this article
Cite this article as:
Ciechomska Anna Iwona, Kocyk Marta and Kaminska Bozena, Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206223501
DOI https://dx.doi.org/10.2174/1574362409666140206223501 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design Harnessing the Power of Cerenkov Luminescence Imaging for Gastroenterology: Cerenkov Luminescence Endoscopy
Current Medical Imaging Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management
Current Pharmaceutical Design Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Subject Index To Volume 7
Current Drug Targets The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets